TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia

Haematologica. 2019 Sep;104(9):e402-e405. doi: 10.3324/haematol.2018.205849. Epub 2019 Jul 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • ETS Translocation Variant 6 Protein
  • Female
  • Follow-Up Studies
  • Genetic Predisposition to Disease
  • Genotype
  • Germ-Line Mutation*
  • Humans
  • Infant
  • Male
  • Neoplasms, Second Primary / genetics*
  • Pilot Projects
  • Polymorphism, Single Nucleotide
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Proto-Oncogene Proteins c-ets / genetics*
  • Repressor Proteins / genetics*
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Core Binding Factor Alpha 2 Subunit
  • Proto-Oncogene Proteins c-ets
  • RUNX1 protein, human
  • Repressor Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53